Retifanlimab Biosimilar – Anti-PDCD1, PD1, CD279 mAb – Research Grade

Introduction

Retifanlimab Biosimilar, also known as anti-PDCD1, PD1, CD279 mAb, is a research-grade monoclonal antibody that is being developed as a potential therapeutic option for various cancers. This biosimilar is designed to target the programmed cell death protein 1 (PD-1) pathway, which plays a critical role in regulating the immune response and preventing the development of cancer. In this article, we will provide a scientific description of the structure, activity, and potential applications of Retifanlimab Biosimilar.

Structure of Retifanlimab Biosimilar

Retifanlimab Biosimilar is a monoclonal antibody that is produced in a laboratory using recombinant DNA technology. It is a protein molecule that is made up of two heavy chains and two light chains, which are connected by disulfide bonds. The heavy chains consist of approximately 450 amino acids, while the light chains consist of about 220 amino acids. The amino acid sequence of Retifanlimab Biosimilar is highly similar to that of the reference product, making it a biosimilar.

Activity of Retifanlimab Biosimilar

Retifanlimab Biosimilar works by binding to the PD-1 receptor on the surface of T cells, which are a type of immune cells. This binding prevents the PD-1 receptor from interacting with its ligands, PD-L1 and PD-L2, which are proteins that are often overexpressed by cancer cells. When PD-1 is blocked, T cells are able to recognize and attack cancer cells more effectively. This can lead to a stronger and more targeted immune response against cancer.

Therapeutic Target of Retifanlimab Biosimilar

The therapeutic target of Retifanlimab Biosimilar is the PD-1 pathway, which is a key regulator of the immune response. This pathway is activated when PD-1 on T cells binds to its ligands, PD-L1 and PD-L2, on other cells in the body. This interaction sends a signal to the T cell to become inactive, which helps to prevent the immune system from attacking healthy cells. However, cancer cells can take advantage of this pathway by overexpressing PD-L1 and PD-L2, thereby evading detection and destruction by the immune system. By targeting the PD-1 pathway, Retifanlimab Biosimilar aims to restore the immune system’s ability to recognize and eliminate cancer cells.

Potential Applications of Retifanlimab Biosimilar

Retifanlimab Biosimilar is being investigated for its potential use in various types of cancer, including melanoma, non-small cell lung cancer, and bladder cancer. It may also have applications in other types of cancer, as well as in combination with other therapies. Currently, Retifanlimab Biosimilar is in preclinical and clinical development, and its safety and efficacy are being evaluated in clinical trials. If approved, it could provide an alternative treatment option for patients with cancer and potentially improve outcomes.

Conclusion

In summary, Retifanlimab Biosimilar is a research-grade monoclonal antibody that targets the PD-1 pathway, a key regulator of the immune response. Its structure, activity, and therapeutic target make it a promising candidate for the treatment of various types of cancer. As research and development of this biosimilar continues, it may offer a new and effective option for patients with cancer.

ProteoGenix catalogue number PX-TA1603. For research use only.

Target: Retifanlimab Biosimilar – Anti-PDCD1, PD1, CD279 mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: Mammalian cells; Purity: >85%; Buffer: PBS buffer PH7.5; Applications: WB, ELISA.

Available configurations: 50ug, 100ug, 1mg.

Download the manufacturer datasheet

Download the manufacturer safety data sheet (MSDS/SDS)